Tumor status at 12 weeks predicts survival in advanced colorectal cancer: Findings from NCCTG N9741

Oncologist

Volumn 16, Issue 6, 2011, Pages 859-867

  Heun, James M ^a   Grothey, Axel ^a   Branda, Megan E ^a   Goldberg, Richard M ^b   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Clinical trial; Colorectal cancer; Endpoints; Tumor status

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; VITAMIN B COMPLEX;

EID: 79959596337     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0064     Document Type: Article

References (34)

1. Allegra C, Blanke C, Buyse M et al. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol 2007;25:3572-3575.
2. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009;27:2874-2880.
3. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004; 22:4442-4445.
4. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-8670.
5. Grothey A. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Stat Methods Med Res 2008;17:529-535.
6. Piedbois P, Buyse M. Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments. Curr Opin Oncol 2008;20:466-471.
7. Buyse M. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer J 2009;15:421-425.
8. Grothey A, Wieand HS, Haller DG et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008;26:183-189.
9. Rubinstein LV, Korn EL, Freidlin B et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23:7199-7206.
10. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-216.
11. Roberts TG Jr., Lynch TJ Jr., Chabner BA. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J Clin Oncol 2003; 21:3683-3695.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
13. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
14. Gan HK, Grothey A, Pond GR et al. Randomized phase II trials: inevitable or inadvisable? J Clin Oncol 2010;28:2641-2647.
15. Tang PA, Bentzen SM, Chen EX et al. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25:4562-4568.
16. Buyse M, Burzykowski T, Carroll K et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25: 5218-5224.
17. Ballman KV, Buckner JC, Brown PD et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007;9:29-38.
18. Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 2009;101:1986-1994.
19. Groves MD, Puduvalli VK, Gilbert MR et al. Two phase II trials of temo-zolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 2009;101:615-620.
20. Aoki T, Mizutani T, Nojima K et al. Phase II study of ifosfamide, carbo-platin, and etoposide in patients with a first recurrence of glioblastoma mul-tiforme. J Neurosurg 2010;112:50-56.
21. Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009;27:2052-2058.
22. Lara PN Jr., Redman MW, Kelly K et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008;26: 463-467.
23. Claret L, Girard P, Hoff PM et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009;27:4103-4108.
24. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
25. Karrison TG, Maitland ML, Stadler WM et al. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007;99:1455-1461.
26. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
27. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
28. Spaepen K, Stroobants S, Dupont P et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-1363.
29. Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376-1381.
30. Mikhaeel NG, Hutchings M, Fields PA et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-1523.
31. Piessevaux H, Buyse M, De Roock W et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory met-astatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol 2009;20:1375-1382.
32. Bystrom P, Berglund A, Garske U et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009;20:1057-1061.
33. Janssen MH, Ollers MC, Riedl RG et al. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemo-therapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys 2010;77: 392-399.
34. Piessevaux H, Bokemeyer C, Schlichting M et al. Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: lessons from the OPUS trial. J Clin Oncol 2011;29(suppl 4; abstr 398).